Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681 | Vol. 03, Issue-03, March-2026 | pp.-46-59

ORIGINALARTICLE https://aktpublication.com/index.php/jprims/index

Neuropharmacology of Novel Antipsychotics: Mechanisms, Efficacy, and Future Directions

Devendra Kumar Sahu[1], Neha Mandle[2], Gautam Dansena[3], Harsh Kumar Tamrakar[4], Deleshwar Kumar[4*]

[1]Faculty of Pharmacy, Kalinga University, Telibandha, Raipur, Chhattisgarh, 492001.
[2]Shri Shankaracharya College of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, 490020.
[3]Shri Balaji College of Pharmaceutical Sciences, Sakti, Chhattisgarh, 495689.
[4]Kamla Institute of Pharmaceutical Sciences, Junwani, Bhilai, Chhattisgarh, 490020
***Corresponding Email: deleshwarkumar54@gmail.com**

Abstract:

D_2 antagonism toward multimodal receptor targeting, glutamatergic modulation, and neuroinflammatory regulation. Despite the success of atypical antipsychotics, limitations such as metabolic side effects, cognitive deficits, and treatment resistance persist. Novel compounds—including third-generation antipsychotics, trace amine-associated receptor 1 (TAAR1) agonists, serotonin–dopamine activity modulators (SDAMs), and glutamatergic agents—are redefining psychopharmacology through receptor-biased signaling, synaptic plasticity enhancement, and neuroimmune modulation. This review consolidates current insights into the neuropharmacological mechanisms of emerging antipsychotics, compares their efficacy and safety profiles, and explores future directions in precision psychiatry, AI-based drug design, and neurocircuit-level therapeutics.

Keywords: Antipsychotics, Dopamine, Serotonin, Glutamate, TAAR1, Neuroinflammation, Receptor Bias, Schizophrenia, Precision Psychiatry, Neuropharmacology.

Received: Dec. 21, 2025 **Revised: Jan. 17, 2026** **Accepted: Feb. 11, 2026** **Published: March. 19, 2026**

DOI: https://doi.org/10.64063/3049-1681.vol.3.issue3.4

https://aktpublication.com/index.php/jprims/issue/archive

1.Introduction

Schizophrenia and related psychotic disorders remain a major global health challenge, affecting over 20 million people worldwide. While current antipsychotic therapies are reasonably effective at controlling positive symptoms such as hallucinations and delusions, they are markedly less effective against negative symptoms—including anhedonia, avolition, and social withdrawal—and cognitive impairments, which are critical determinants of functional outcomes [1]. Alarmingly, 30–40% of patients demonstrate partial or no response to existing medications, leaving a substantial unmet clinical need. These limitations have spurred research into novel

mechanisms of action that extend beyond conventional dopaminergic blockade, aiming to modulate broader neural circuits implicated in psychosis [2]. The history of antipsychotic therapy reflects decades of refinement and innovation. Starting with chlorpromazine in the 1950s, the first antipsychotic to demonstrate robust efficacy against psychosis, the field advanced to clozapine, the atypical antipsychotic that set new standards in efficacy, particularly for treatment-resistant patients, while reducing extrapyramidal side effects [3]. More recent agents, such as cariprazine and lumateperone**,** represent the third generation of antipsychotics, characterized by functional selectivity—the ability to fine-tune receptor signaling pathways rather than simply activating or blocking them outright [4]. These advances highlight a trend toward drugs that not only control psychotic symptoms but also aim to improve overall cognitive and social functioning. Modern antipsychotic research has shifted focus from simple dopamine receptor antagonism to a more nuanced understanding of neurotransmission and neural networks [5]. Current strategies explore receptor bias**,** intracellular signaling modulation**,** and network-level plasticity, targeting dopaminergic, serotonergic, glutamatergic, and GABAergic systems in a coordinated manner [6]. The overarching goal is to restore neurotransmitter balance**,** improve synaptic plasticity, and enhance functional connectivity, thereby addressing not just the overt symptoms of psychosis but also the underlying cognitive and negative symptom burden that critically affects patients' quality of life [7]. This evolution reflects a broader paradigm shift in neuropsychopharmacology: moving from broad, blunt interventions toward precision-targeted therapies that modulate neural circuits with greater specificity, efficacy, and safety.

2.**Dopaminergic Mechanisms: The Core and Beyond**

The dopamine hypothesis has long served as the cornerstone of schizophrenia research. Traditionally, it is posited that hyperactivity in mesolimbic dopamine pathways drives positive symptoms, such as hallucinations and delusions, while hypoactivity in mesocortical dopamine circuits underlies negative symptoms and cognitive deficits [8]. Although this framework retains partial validity, contemporary evidence from advanced imaging and postmortem studies paints a more nuanced picture. Findings indicate region-specific alterations in dopamine receptor density**,** changes in synthesis capacity**,** and dysregulated interactions between dopamine and glutamate systems, suggesting that effective symptom control requires a more targeted and circuit-specific approach rather than blanket dopamine blockade [9-10]. Emerging antipsychotics leverage the concept of partial agonism, particularly at dopamine D_2 and D_3 receptors, to modulate neurotransmission without fully inhibiting it [11]. Agents like aripiprazole, brexpiprazole, and cariprazine fine-tune receptor activity, maintaining adequate dopaminergic tone while minimizing extrapyramidal side effects (EPS) associated with full antagonism. For instance**,** cariprazine exhibits preferential D_3 receptor binding, which has been linked to improvements in negative and cognitive symptoms. Similarly**,** aripiprazole acts as a "dopamine stabilizer," balancing overactive and underactive pathways to provide symptom relief without disrupting normal dopaminergic signaling [12-13]. (Table 1)D_3 receptors, primarily located in limbic regions, play a critical role in motivation, reward processing, and emotional regulation**.** Selective targeting of these receptors, as seen with blonanserin and cariprazine, offers the potential to

address domains historically resistant to treatment, such as mood disturbances and cognitive deficits [14]. By modulating D_3-mediated pathways, these compounds represent a therapeutic advancement beyond traditional dopamine-centric strategies, providing a more holistic approach to symptom management and functional recovery in schizophrenia. Overall, modern dopaminergic strategies are shifting from broad receptor blockade to precision modulation, integrating receptor selectivity and functional bias to improve efficacy, tolerability, and patient outcomes [15]. (Figure 1)

Figure 1: Comparison of Mesolimbic and Mesocortical Dopamine Pathways: Dopamine Receptor Roles and Pharmacological Modulation



Table 1. Dopaminergic Properties of Novel Antipsychotics

Drug	Primary Mechanism	Receptor Profile	Benefit	Reference
Aripiprazole	D_2/D_3 partial agonist	D_2 > 5-HT_1A > 5-HT_2A	Reduced EPS	16
Cariprazine	D_3 > D_2 partial agonist	D_3/D_2 ratio 10:1	Improves negative symptoms	17

Brexpiprazole	D_2 partial agonist, 5-HT_1A agonist	Balanced dopaminergic/serotonergic	Anxiolytic, low akathisia	18

3.Serotonergic and Multimodal Mechanisms

Beyond dopamine, serotonin (5-HT) neurotransmission plays a crucial modulatory role in schizophrenia. Specific receptors, particularly 5-HT_2A and 5-HT_1A**,** influence dopamine release in both cortical and limbic regions [19]. Antagonism of 5-HT_2A receptors indirectly increases dopaminergic activity in the prefrontal cortex, thereby counteracting the cognitive dulling and negative symptom burden often seen with first-generation antipsychotics. This serotonergic modulation creates a more balanced neurotransmitter environment**,** enhancing cognition and improving overall functional outcomes [20-21]. The development of serotonin-dopamine activity modulators (SDAMs) represents a significant advance in antipsychotic therapy. Drugs such as lumateperone and lurasidone are designed to harmonize both dopaminergic and serotonergic tone. For example, lumateperone exhibits a triple mechanism of action: antagonism at 5-HT_2A receptors, partial modulation of D_2 receptors, and enhancement of glutamatergic signaling [23-24]. This multimodal profile differentiates it from traditional antipsychotics, positioning lumateperone as a distinct neuropharmacological class capable of addressing positive, negative, and cognitive symptoms simultaneously. Emerging research highlights additional serotonin receptor subtypes as potential therapeutic targets**.** 5-HT_6 and 5-HT_7 antagonists have demonstrated procognitive effects in preclinical studies, offering hope for improving learning and memory deficits in schizophrenia [25-26]. Moreover, 5-HT_1A receptor agonism**,** a feature of lurasidone and brexpiprazole, contributes to anxiolytic and antidepressant benefits**,** addressing comorbid mood symptoms that often complicate the disorder. By integrating serotonergic modulation with dopaminergic pathways, modern antipsychotics achieve a multimodal approach, targeting a wider spectrum of symptoms while minimizing adverse effects. This shift represents a more holistic strategy, focusing not only on symptom suppression but also on restoring neurochemical balance and enhancing overall brain function [27-28].

4.Glutamatergic Pathways and NMDA Modulation

In recent years, research has increasingly highlighted glutamatergic dysfunction as a central feature of schizophrenia. Emerging from models using PCP and ketamine**,** the glutamate hypothesis proposes that hypofunction of NMDA receptors on inhibitory interneurons leads to cortical disinhibition and subsequent dopaminergic imbalance [29-30]. This perspective helps explain symptoms that are poorly addressed by traditional dopaminergic antipsychotics, particularly negative symptoms and cognitive deficits**,** emphasizing the need for therapies that restore glutamatergic signaling [31]. Targeting the NMDA receptor via its glycine co-agonist site represents one promising approach. Compounds such as D-serine, sarcosine**,** and glycine

transporter-1 (GlyT1) inhibitors enhance NMDA receptor function, aiming to rebalance excitatory neurotransmission. For instance, bitopertin**,** a GlyT1 inhibitor, demonstrated symptomatic improvements in early clinical trials, though it has yet to receive FDA approval [32-33]. These agents highlight the therapeutic potential of fine-tuning receptor co-agonism to improve both negative and cognitive symptoms without exacerbating positive symptoms. Beyond NMDA receptors, metabotropic glutamate receptors (mGluRs) offer additional avenues for intervention. mGluR2/3 agonists**,** such as LY2140023, have shown promise in attenuating positive symptoms with a favorable side-effect profile [34-35]. Meanwhile, mGluR5 positive allosteric modulators (PAMs) may restore synaptic plasticity and improve cognitive function by enhancing receptor responsiveness without triggering excitotoxicity. Modulating these receptors represents a network-level strategy**,** aiming to rebalance excitatory-inhibitory signaling across cortical circuits and complement traditional dopaminergic and serotonergic approaches [36-37]. Collectively, targeting glutamatergic pathways broadens the therapeutic landscape, offering hope for symptoms resistant to conventional antipsychotics and paving the way for more comprehensive, multimodal treatments in schizophrenia.

5. Novel Targets and Mechanistic Innovations

A recent breakthrough in schizophrenia pharmacology is the targeting of Trace Amine-Associated Receptor 1 (TAAR1)**,** which modulates monoaminergic transmission without directly interacting with dopamine D_2 receptors. Ulotaront (SEP-363856)**,** a selective TAAR1 agonist, has demonstrated robust antipsychotic efficacy in phase III clinical trials**,** offering a novel mechanism that bypasses the traditional dopaminergic pathway [38]. This approach represents a new receptor paradigm**,** potentially minimizing side effects such as extrapyramidal symptoms while addressing both positive and negative symptoms. Increasing evidence implicates neuroinflammatory processes in the pathophysiology of schizophrenia. Chronic microglial activation and imbalances in cytokine signaling contribute to synaptic dysfunction and neuronal damage [39-40]. Therapeutic strategies targeting these pathways are emerging, with agents like minocycline and P2X7 receptor antagonists being explored as adjunctive or hybrid antipsychotics**.** By modulating immune responses in the brain, these compounds aim to restore synaptic integrity and complement traditional neurotransmitter-targeted therapies [41-42]. Beyond receptor-level interventions, modern drug development increasingly focuses on enhancing intracellular signaling and neuroplasticity. Compounds designed to activate pathways such as BDNF, CREB, and Akt/GSK-3β promote neurogenesis, strengthen synaptic connections, and improve neuronal resilience [43-44]. This strategy shifts the therapeutic paradigm from merely correcting neurotransmitter imbalances to restoring the underlying cellular and network architecture of the brain, potentially leading to durable improvements in cognitive function and overall functional outcomes [45]. Together, these novel targets—TAAR1 modulation, immunoneuropsychiatric interventions, and intracellular signaling enhancement—represent a mechanistic evolution in schizophrenia treatment. They expand the therapeutic toolkit beyond traditional dopaminergic and serotonergic frameworks, aiming for broader efficacy, improved safety, and enhanced patient functionality [46].

6. **Efficacy and Comparative Clinical Outcomes**

The clinical performance of novel antipsychotics reflects the growing emphasis on efficacy, safety, and functional improvement beyond traditional symptom control. Comparative studies against established agents such as risperidone provide a clear picture of how these next-generation drugs are reshaping schizophrenia treatment [47]. Cariprazine, a D_3-preferring dopamine partial agonist, has demonstrated FDA-approved efficacy in phase III trials. It shows comparable effectiveness to risperidone in controlling positive symptoms while offering a low risk of weight gain and significant improvement in negative and cognitive symptoms, highlighting its functional advantage [48-49]. Lumateperone, with its multimodal mechanism involving serotonin-dopamine modulation and glutamatergic enhancement, has shown non-inferior efficacy in phase III trials relative to risperidone. Its metabolic profile is favorable, with minimal effects on weight and glucose levels, while providing mild improvements in negative symptoms. Ulotaront, the TAAR1 agonist, represents a novel mechanism entirely independent of D_2 blockade [50]. Phase III trials indicate efficacy similar to standard antipsychotics, combined with an excellent metabolic profile and moderate improvements in negative and cognitive symptoms, positioning it as a promising alternative for patients sensitive to dopaminergic side effects. Lurasidone also demonstrates non-inferior efficacy against risperidone but is distinguished by its cognitive-enhancing effects and neutral impact on metabolic parameters [51-52]. This makes it particularly attractive for patients where cognitive deficits are a primary concern. Overall, these comparative outcomes underscore that modern antipsychotics are not only effective in controlling positive symptoms but are increasingly tailored to address metabolic safety and functional deficits, marking a significant advancement over earlier-generation therapies. The integration of receptor selectivity, multimodal activity, and novel mechanisms like TAAR1 agonism reflects a more patient-centered, precision approach to schizophrenia management [53-54].

7.**Safety and Side Effect Profile**

One of the major limitations of second-generation antipsychotics like clozapine and olanzapine is their propensity to induce metabolic disturbances**,** including weight gain, hyperglycemia, and dyslipidemia, which significantly increase long-term cardiovascular risk. In contrast, newer antipsychotics have been designed with reduced affinity for 5-HT_2C and H_1 receptors**,** mitigating these adverse effects [55-56]. Agents such as cariprazine, lumateperone, and lurasidone demonstrate low **to** minimal impact on weight, glucose, and lipid profiles**,** making them safer for long-term use, particularly in populations already at risk for metabolic syndrome. Traditional D_2 antagonists often produce extrapyramidal symptoms (EPS) and hyperprolactinemia, complicating adherence and quality of life [57]. Third-generation partial agonists, including aripiprazole, brexpiprazole, and cariprazine**,** maintain dopaminergic tone**,** effectively lowering the incidence of EPS and prolactin elevation. This pharmacological refinement not only improves tolerability but also enhances treatment adherence and patient comfort**,** which are critical for long-term management [58]. A transformative aspect of modern

antipsychotics is their impact on cognitive and affective domains, historically neglected by first- and second-generation drugs. By integrating serotonergic and glutamatergic modulation, these agents provide mild-to-moderate improvements in cognition, motivation, and mood, helping patients achieve better functional outcomes [59]. For example, D_3-preferring drugs like cariprazine and multimodal compounds like lumateperone not only control positive symptoms but also support executive function, working memory, and emotional regulation, marking a significant step toward holistic symptom management in schizophrenia. Overall, the safety and tolerability profiles of these novel antipsychotics reflect a deliberate shift toward precision pharmacology, balancing efficacy with reduced adverse effects and improved cognitive and emotional function, ultimately enhancing quality of life and long-term prognosis.

8. Future Directions

The era of precision psychiatry is on the horizon, driven by advances in pharmacogenomics and neuroimaging. Genetic markers such as DRD2 polymorphisms, COMT variants, and other neurotransmitter-related alleles can help predict individual responses to antipsychotics, guiding personalized drug selection. Similarly, neuroimaging biomarkers provide insight into circuit-level dysfunction, enabling clinicians to tailor therapy based on specific patterns of cortical and limbic activity [60]. Together, these approaches promise a shift from empirical prescribing to data-driven, patient-specific treatment strategies, optimizing efficacy while minimizing side effects. Artificial intelligence is rapidly transforming antipsychotic drug discovery. Deep learning algorithms, molecular docking AI, and generative models accelerate the identification of receptor-biased ligands and polypharmacological compounds with enhanced safety and efficacy profiles [61-62]. By simulating receptor interactions, predicting pharmacokinetics, and screening vast chemical libraries virtually, AI drastically reduces development timelines and resource requirements, enabling the next generation of highly targeted, rationally designed antipsychotics. Future antipsychotics are expected to act beyond individual receptors, targeting specific neural circuits implicated in schizophrenia [63-64]. Insights from optogenetics, chemogenetics, and neuromodulation studies suggest that modulating prefrontal-limbic connectivity can improve cognition, emotion regulation, and negative symptoms. Drug candidates designed with these circuit-level principles may fine-tune synaptic activity, restore functional connectivity, and produce more holistic symptom relief than traditional receptor-centric approaches [65]. The traditional "one-drug-one-target" paradigm is giving way to polypharmacology, where a single compound modulates multiple neurotransmitter systems simultaneously. Future antipsychotics are likely to balance dopaminergic, serotonergic, glutamatergic, and neuroinflammatory pathways, addressing the complex pathophysiology of schizophrenia more comprehensively [66-67]. Such hybrid and multi-target ligands aim not only to suppress positive symptoms but also to enhance cognition, mood, and functional outcomes, reflecting a truly integrative approach to treatment. In summary, the future of antipsychotic therapy lies in precision, multimodal, and circuit-informed strategies, integrating genetics, AI, and neurobiology to create safer, more effective, and patient-tailored treatments that go far beyond symptom suppression [68-69].

9.Conclusion

The development of novel antipsychotics marks a transformative era in neuropharmacology, representing a true renaissance in psychotropic innovation. Modern compounds integrate receptor-biased signaling, serotonergic and glutamatergic modulation, TAAR1 agonism, and neuroimmune regulation, collectively redefining the boundaries of efficacy, tolerability, and functional improvement. Although a perfect antipsychotic—one that fully restores cognition, mood, and motivation without side effects—remains elusive, the trajectory of research is unmistakable. Therapy is shifting from broad dopamine blockade toward precision circuit modulation, from mere symptom suppression toward the promotion of neurofunctional recovery**.** The next generation of antipsychotics promises not only to manage schizophrenia but also to remodel neural circuits**,** potentially enabling sustained remission, improved quality of life, and a more holistic restoration of brain function. This evolution underscores a future in which treatment is mechanistically sophisticated, patient-centered, and functionally restorative**,** heralding a new standard in psychiatric care.

References

1. Moreno-Küstner, B., Martín, C., & Pastor, L. (2018). Prevalence of psychotic disorders and its association with methodological issues: A systematic review and meta-analyses. *PLOS ONE, 13,* e0195687. https://doi.org/10.1371/journal.pone.0195687
2. Howes, O. D., & Kapur, S. (2009). The dopamine hypothesis of schizophrenia: Version III—the final common pathway. *Schizophrenia Bulletin, 35*(3), 549–562. https://doi.org/10.1093/schbul/sbp006
3. Kambeitz, J., Abi-Dargham, A., Kapur, S., & Howes, O. D. (2014). Alterations in cortical and extrastriatal subcortical dopamine function in schizophrenia: Systematic review and meta-analysis of imaging studies. *British Journal of Psychiatry, 204*(5), 420–429. https://doi.org/10.1192/bjp.bp.113.135164
4. López-Muñoz, F., Alamo, C., Cuenca, E., Shen, W. W., Clervoy, P., & Rubio, G. (2005). History of the discovery and clinical introduction of chlorpromazine. *Annals of Clinical Psychiatry, 17*(3), 113–135. https://doi.org/10.1080/10401230500126071
5. Nucifora, F. C., Woznica, E., Lee, B. J., Cascella, N., & Sawa, A. (2019). Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. *Neurobiology of Disease, 131,* 104257. https://doi.org/10.1016/j.nbd.2019.104257
6. Girgis, R. R., Zoghbi, A. W., Javitt, D. C., & Lieberman, J. A. (2019). The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review. *Journal of Psychiatric Research, 108,* 57–83. https://doi.org/10.1016/j.jpsychires.2018.12.003
7. Reichenberg, A., Feo, C., Prestia, D., Bowie, C. R., Patterson, T. L., & Harvey, P. D. (2014). The course and correlates of everyday functioning in schizophrenia. *Schizophrenia Research: Cognition, 1,* e47–e52. https://doi.org/10.1016/j.scog.2014.05.001

8. Milev, P., Ho, B.-C., Arndt, S., & Andreasen, N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: A longitudinal first-episode study with 7-year follow-up. *American Journal of Psychiatry, 162*(3), 495–506. https://doi.org/10.1176/appi.ajp.162.3.495
9. McCutcheon, R. A., Krystal, J. H., & Howes, O. D. (2020). Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment. *World Psychiatry, 19*(1), 15–33. https://doi.org/10.1002/wps.20787
10. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. *Annual Review of Pharmacology and Toxicology, 41,* 237–260. https://doi.org/10.1146/annurev.pharmtox.41.1.237
11. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. *Biological Psychiatry, 70*(7), 663–671. https://doi.org/10.1016/j.biopsych.2011.04.013
12. Howes, O. D., & Kapur, S. (2014). A neurobiological hypothesis for the classification of schizophrenia: Type A (hyperdopaminergic) and type B (normodopaminergic). *British Journal of Psychiatry, 205*(1), 1–3. https://doi.org/10.1192/bjp.bp.113.139313
13. Hauser, T. A., Kucinski, A., Jordan, K. G., Gatto, G. J., Wersinger, S. R., Hesse, R. A., … et al. (2009). TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. *Biochemical Pharmacology, 78*(7), 803–812. https://doi.org/10.1016/j.bcp.2009.06.012
14. Walling, D., Marder, S. R., Kane, J., Fleischhacker, W. W., Keefe, R. S. E., Hosford, D. A., … et al. (2016). Phase 2 trial of an alpha-7 nicotinic receptor agonist (TC-5619) in negative and cognitive symptoms of schizophrenia. *Schizophrenia Bulletin, 42*(2), 335–343. https://doi.org/10.1093/schbul/sbv097
15. Kumari, S., Malik, M., Florival, C., Manalai, P., & Sonje, S. (2017). An assessment of five (PANSS, SAPS, SANS, NSA-16, CGI-SCH) commonly used symptom rating scales in schizophrenia and comparison to newer scales (CAINS, BNSS). *Journal of Addiction Research & Therapy, 8,* 324. https://doi.org/10.4172/2155-6105.1000324
16. Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., … et al. (2013). Clinical trials of potential cognitive-enhancing drugs in schizophrenia: What have we learned so far? *Schizophrenia Bulletin, 39*(2), 417–435. https://doi.org/10.1093/schbul/sbs171
17. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., … et al. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. *Nature Reviews Drug Discovery, 9*(3), 203–214. https://doi.org/10.1038/nrd3078
18. Walling, D. P., Banerjee, A., Dawra, V., Boyer, S., Schmidt, C. J., & DeMartinis, N. (2019). Phosphodiesterase 10A inhibitor monotherapy is not an effective treatment of acute schizophrenia. *Journal of Clinical Psychopharmacology, 39*(5), 575–582. https://doi.org/10.1097/JCP.0000000000001092

19. Macek, T. A., McCue, M., Dong, X., Hanson, E., Goldsmith, P., Affinito, J., … et al. (2019). A phase 2, randomized, placebo-controlled study of the efficacy and safety of TAK-063 in subjects with an acute exacerbation of schizophrenia. *Schizophrenia Research, 204,* 289–294. https://doi.org/10.1016/j.schres.2018.09.037
20. Bugarski-Kirola, D., Blaettler, T., Arango, C., Fleischhacker, W. W., Garibaldi, G., Wang, A., … et al. (2017). Bitopertin in negative symptoms of schizophrenia—Results from the phase III flashlyte and daylyte studies. *Biological Psychiatry, 82*(1), 8–16. https://doi.org/10.1016/j.biopsych.2017.02.1133
21. Neurocrine Biosciences, Inc. (2021, January). Neurocrine Biosciences announces top-line results from phase II INTERACT study evaluating luvadaxistat (NBI-1065844) for the treatment of negative symptoms and cognitive impairment associated with schizophrenia (CIAS). *Neurocrine Biosciences, Inc.* https://investor.neurocrine.com/news-releases
22. Adams, D. H., Kinon, B. J., Baygani, S., Millen, B. A., Velona, I., Kollack-Walker, S., … et al. (2013). A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia. *BMC Psychiatry, 13,* 143. https://doi.org/10.1186/1471-244X-13-143
23. Downing, A. M., Kinon, B. J., Millen, B. A., Zhang, L., Liu, L., Morozova, M. A., … et al. (2014). A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. *BMC Psychiatry, 14,* 351. https://doi.org/10.1186/s12888-014-0351-5
24. Brannan, S. K. (2019). 32.2 Two global phase III trials of encenicline for cognitive impairment in chronic schizophrenia patients: Red flags and lessons learned. *Schizophrenia Bulletin, 45*(S1), S141–S142. https://doi.org/10.1093/schbul/sbz072
25. Huang, M., Felix, A. R., Flood, D. G., Bhuvaneswaran, C., Hilt, D., Koenig, G., … et al. (2014). The novel α7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. *Psychopharmacology, 231*(23), 4541–4551. https://doi.org/10.1007/s00213-014-3567-4
26. Arai, A. C., & Kessler, M. (2007). Pharmacology of ampakine modulators: From AMPA receptors to synapses and behavior. *Current Drug Targets, 8*(6), 583–602. https://doi.org/10.2174/138945007781386191
27. Goff, D. C., Lamberti, J. S., Leon, A. C., Green, M. F., Miller, A. L., Patel, J., … et al. (2008). A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. *Neuropsychopharmacology, 33*(3), 465–472. https://doi.org/10.1038/sj.npp.1301403
28. Ranganathan, M., DeMartinis, N., Huguenel, B., Gaudreault, F., Bednar, M. M., Shaffer, C. L., … et al. (2017). Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242. *Molecular Psychiatry, 22*(11), 1633–1640. https://doi.org/10.1038/mp.2016.170
29. Stahl, S. M. (2013). Mechanism of action of ketamine. *CNS Spectrums, 18*(3), 171–174. https://doi.org/10.1017/S1092852913000374

30. Mouchlianitis, E., Bloomfield, M. A., Law, V., Beck, K., Selvaraj, S., Rasquinha, N., … et al. (2016). Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. *Schizophrenia Bulletin, 42*(4), 744–752. https://doi.org/10.1093/schbul/sbv158
31. Yun, S., Yang, B., Martin, M. M., Yeh, N.-H., Contractor, A., & Parker, J. G. (2021). Modulating D1 rather than D2 receptor-expressing spiny-projection neurons corresponds to optimal antipsychotic effect. *bioRxiv*. https://doi.org/10.1101/2021.08.03.454992
32. Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R., … et al. (2020). A non-D2-receptor-binding drug for the treatment of schizophrenia. *New England Journal of Medicine, 382*(16), 1497–1506. https://doi.org/10.1056/NEJMoa1915109
33. Heffernan, M. L. R., Herman, L. W., Brown, S., Jones, P. G., Shao, L., Hewitt, M. C., … et al. (2022). Ulotaront: A TAAR1 agonist for the treatment of schizophrenia. *ACS Medicinal Chemistry Letters, 13*(1), 92–98. https://doi.org/10.1021/acsmedchemlett.1c00620
34. Demjaha, A., Murray, R. M., McGuire, P. K., Kapur, S., & Howes, O. D. (2012). Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. *American Journal of Psychiatry, 169*(11), 1203–1210. https://doi.org/10.1176/appi.ajp.2012.11101519
35. Dedic, N., Jones, P. G., Hopkins, S. C., Lew, R., Shao, L., Campbell, J. E., … et al. (2019). SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. *Journal of Pharmacology and Experimental Therapeutics, 371*(1), 1–14. https://doi.org/10.1124/jpet.119.258301
36. Begni, V., Sanson, A., Luoni, A., Sensini, F., Grayson, B., Munni, S., … et al. (2021). Towards novel treatments for schizophrenia: Molecular and behavioural signatures of the psychotropic agent SEP-363856. *International Journal of Molecular Sciences, 22*(8), 4119. https://doi.org/10.3390/ijms22084119
37. Brannan, S. K., Sawchak, S., Miller, A. C., Lieberman, J. A., Paul, S. M., & Breier, A. (2021). Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. *New England Journal of Medicine, 384*(8), 717–726. https://doi.org/10.1056/NEJMoa2022413
38. Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., … et al. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. *Archives of Neurology, 54*(4), 465–473. https://doi.org/10.1001/archneur.1997.00550160041013
39. Shekhar, A., Potter, W. Z., Lightfoot, J., Lienemann, J., Dubé, S., Mallinckrodt, C., … et al. (2008). Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. *American Journal of Psychiatry, 165*(8), 1033–1039. https://doi.org/10.1176/appi.ajp.2008.07121875
40. Woolley, M. L., Carter, H. J., Gartlon, J. E., Watson, J. M., & Dawson, L. A. (2009). Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated

in muscarinic M1 receptor knockout mice. *European Journal of Pharmacology, 603*(1–3), 147–149. https://doi.org/10.1016/j.ejphar.2008.11.014

41. Thorn, C. A., Moon, J., Bourbonais, C. A., Harms, J., Edgerton, J. R., Stark, E., … et al. (2019). Striatal, hippocampal, and cortical networks are differentially responsive to the M4- and M1-muscarinic acetylcholine receptor mediated effects of xanomeline. *ACS Chemical Neuroscience, 10*(4), 1753–1764. https://doi.org/10.1021/acschemneuro.8b00644
42. Krystal, J. H., Kane, J. M., Correll, C. U., Walling, D. P., Leoni, M., Duvvuri, S., … et al. (2021). CVL231 as a novel positive allosteric modulator of cholinergic M4 receptors for the treatment of schizophrenia: Results from an early proof-of-concept study in patients with schizophrenia. *Neuropsychopharmacology, 46*(S1), 218–368. https://doi.org/10.1038/s41386-021-01018-1
43. Brown, A. J. H., Bradley, S. J., Marshall, F. H., Brown, G. A., Bennett, K. A., Brown, J., … et al. (2021). From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treat Alzheimer's disease. *Cell, 184*(22), 5886–5901.e22. https://doi.org/10.1016/j.cell.2021.08.026
44. Gould, R. W., Grannan, M. D., Gunter, B. W., Ball, J., Bubser, M., Bridges, T. M., … et al. (2018). Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154. *Neuropharmacology, 128,* 492–502. https://doi.org/10.1016/j.neuropharm.2017.11.009
45. Jones, C. A., Watson, D. J. G., & Fone, K. C. F. (2011). Animal models of schizophrenia. *British Journal of Pharmacology, 164*(4), 1162–1194. https://doi.org/10.1111/j.1476-5381.2011.01460.x
46. Gainetdinov, R. R., Mohn, A. R., & Caron, M. G. (2001). Genetic animal models: Focus on schizophrenia. *Trends in Neurosciences, 24*(10), 527–533. https://doi.org/10.1016/S0166-2236(00)01960-1
47. Winship, I. R., Dursun, S. M., Baker, G. B., Balista, P. A., Kandratavicius, L., Maia-de-Oliveira, J. P., … et al. (2019). An overview of animal models related to schizophrenia. *Canadian Journal of Psychiatry, 64*(1), 5–17. https://doi.org/10.1177/0706743718808687
48. Zheutlin, A. B., Dennis, J., Karlsson Linnér, R., Moscati, A., Restrepo, N., Straub, P., … et al. (2019). Penetrance and pleiotropy of polygenic risk scores for schizophrenia in 106,160 patients across four health care systems. *American Journal of Psychiatry, 176*(10), 846–855. https://doi.org/10.1176/appi.ajp.2019.18091005
49. Lipska, B. K., & Weinberger, D. R. (2000). To model a psychiatric disorder in animals: Schizophrenia as a reality test. *Neuropsychopharmacology, 23*(3), 223–239. https://doi.org/10.1016/S0893-133X(00)00111-4
50. Bell, D. S. (1973). The experimental reproduction of amphetamine psychosis. *Archives of General Psychiatry, 29*(1), 35–40. https://doi.org/10.1001/archpsyc.1973.01750130059005
51. Connell, P. H. (1957). Amphetamine psychosis. *British Medical Journal, 1*(5021), 582. https://doi.org/10.1136/bmj.1.5021.582

52. Seeman, P., & Lee, T. (1975). Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. *Science, 188*(4194), 1217–1219. https://doi.org/10.1126/science.1155061
53. Powell, C. M., & Miyakawa, T. (2006). Schizophrenia-relevant behavioral testing in rodent models: A uniquely human disorder? *Biological Psychiatry, 59*(12), 1198–1207. https://doi.org/10.1016/j.biopsych.2005.12.007
54. Arguello, P. A., & Gogos, J. A. (2006). Modeling madness in mice: One piece at a time. *Neuron, 52*(1), 179–196. https://doi.org/10.1016/j.neuron.2006.09.003
55. Mclean, J. R., Parker, R. B., & Coughenour, L. L. (1978). Effect of antipsychotic and other classes of drugs on spontaneous locomotor activity and neurotoxicity in mice. *Pharmacology Biochemistry and Behavior, 8*(1), 97–99. https://doi.org/10.1016/0091-3057(78)90054-0
56. Schmack, K., Bosc, M., Ott, T., Sturgill, J. F., & Kepecs, A. (2021). Striatal dopamine mediates hallucination-like perception in mice. *Science, 372*(6540), eabf4740. https://doi.org/10.1126/science.abf4740
57. Kesby, J. P., Eyles, D. W., McGrath, J. J., & Scott, J. G. (2018). Dopamine, psychosis and schizophrenia: The widening gap between basic and clinical neuroscience. *Translational Psychiatry, 8*(1), 1–12. https://doi.org/10.1038/s41398-018-0149-7
58. Luo, M., Fee, M. S., & Katz, L. C. (2003). Encoding pheromonal signals in the accessory olfactory bulb of behaving mice. *Science, 299*(5610), 1196–1201. https://doi.org/10.1126/science.1078862
59. Moberg, P. J., Agrin, R., Gur, R. E., Gur, R. C., Turetsky, B. I., & Doty, R. L. (1999). Olfactory dysfunction in schizophrenia: A qualitative and quantitative review. *Neuropsychopharmacology, 21*(3), 325–340. https://doi.org/10.1016/S0893-133X(99)00006-7
60. Shamsi, S., Lau, A., Lencz, T., Burdick, K. E., DeRosse, P., Brenner, R., … et al. (2011). Cognitive and symptomatic predictors of functional disability in schizophrenia. *Schizophrenia Research, 126*(1–3), 257–264. https://doi.org/10.1016/j.schres.2010.11.020
61. Green, M. F. (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? *American Journal of Psychiatry, 153*(3), 321–330. https://doi.org/10.1176/ajp.153.3.321
62. Harvey, P. D., Howanitz, E., Parrella, M., White, L., Davidson, M., Mohs, R. C., … et al. (1998). Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: A comparison across treatment sites. *American Journal of Psychiatry, 155*(8), 1080–1086. https://doi.org/10.1176/ajp.155.8.1080
63. Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., … et al. (2011). A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. *Biological Psychiatry, 69*(5), 442–449. https://doi.org/10.1016/j.biopsych.2010.09.037
64. Callahan, P. M., Terry, A. V., & Tehim, A. (2014). Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor

gating and recognition memory in rats. *Psychopharmacology, 231*(18), 3695–3706. https://doi.org/10.1007/s00213-014-3543-0

65. Damgaard, T., Larsen, D. B., Hansen, S. L., Grayson, B., Neill, J. C., & Plath, N. (2010). Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. *Behavioural Brain Research, 207*(1), 144–150. https://doi.org/10.1016/j.bbr.2009.11.020
66. Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., … et al. (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. *American Journal of Psychiatry, 165*(9), 1040–1047. https://doi.org/10.1176/appi.ajp.2008.07091484
67. Freudenreich, O., Henderson, D. C., Macklin, E. A., Evins, A. E., Fan, X., Cather, C., … et al. (2009). Modafinil for clozapine-treated schizophrenia patients: A double-blind, placebo-controlled pilot trial. *Journal of Clinical Psychiatry, 70*(11), 1674–1680. https://doi.org/10.4088/JCP.08m04877
68. Friedman, J. I., Carpenter, D., Lu, J., Fan, J., Tang, C. Y., White, L., … et al. (2008). A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. *Journal of Clinical Psychopharmacology, 28*(1), 59–63. https://doi.org/10.1097/JCP.0b013e318160b0b7
69. Karamihalev, S., Prickaerts, J., & van Goethem, N. P. (2014). Donepezil and the alpha-7 agonist PHA 568487, but not risperidone, ameliorate spatial memory deficits in a subchronic MK-801 mouse model of cognitive impairment in schizophrenia. *Behavioural Brain Research, 272,* 248–251. https://doi.org/10.1016/j.bbr.2014.07.028